A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

NCT03780543 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

92

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Chronic Hepatitis B

Interventions

DRUG: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)

Sponsor

Assembly Biosciences